BACKGROUND AND AIMS Hepatitis B virus-related decompensated cirrhosis is difficult to cure but has a high readmission rate due to multiple complications. Our aim was to investigate the diagnostic potential value of plasma diamine oxidase (DAO) for 6-month readmission of patients with HBV-related decompensated cirrhosis. METHODS A total of 135 patients with HBV-related decompensated cirrhosis were prospectively collected at the onset of discharge of hospital, and then were followed up for at least 6 months with the readmission as the primary outcome. The plasma DAO level was measured using enzyme linked immunosorbent assay. In addition, 120 age and sex matched patients with HBV-related compensated cirrhosis were included as controls. RESULTS A total of 36 patients (36.7%) with decompensated cirrhosis admitted to hospital during the 6-month follow up. The plasma DAO level of readmission group [21.1 (14.5; 29.0) ng/ml] was significantly higher than that in the non-readmission group [12.7 (9.3; 18.0) ng/mL, P < 0.001]. Multivariate analysis showed that the plasma DAO level (HR = 1.102, P < 0.05) and hepatic encephalopathy (HE) (HR = 5.018, P < 0.05) were independent factors for 6-month readmission of decompensated cirrhosis. DAO level showed higher area under the curve of receiver operating characteristic (AUROC) than HE (0.769 vs. 0.598, P < 0.05) and Child-Pugh-Turcotte (CPT) score (0.769 vs. 0.652, P < 0.05) for predicting 6-month readmission rate, with the best cut-off value as 19.7 ng/mL. Furthermore, plasma DAO level (HR = 1.184, P < 0.05) was an independent factor and has the higher AUROC than CPT score for the onset of recurrent HE (0.905 vs. 0.738, P < 0.05) during the 6-month follow up. CONCLUSIONS Plasma DAO level > 19.7 ng/mL predicts high rate of 6-month readmission in patients with HBV-related decompensated cirrhosis.

中文翻译：

---

血浆二胺氧化酶水平可预测乙型肝炎病毒相关失代偿性肝硬化患者的6个月再入院。

背景与目的乙肝病毒相关的失代偿性肝硬化难以治愈，但由于多种并发症而具有较高的再入院率。我们的目的是研究血浆二胺氧化酶（DAO）对HBV相关代偿性肝硬化患者6个月再入院的诊断潜力。方法前瞻性收集出院时收集的135例HBV相关代偿失调性肝硬化患者，然后随访至少6个月，以再次入院为主要结局。使用酶联免疫吸附测定法测量血浆DAO水平。另外，将120名年龄和性别相匹配的HBV相关性代偿性肝硬化患者作为对照。结果共有36例患者（36。失代偿性肝硬化的7％）在6个月的随访期间入院。再入组的血浆DAO水平为[21.1（14.5; 29.0）ng / ml]，显着高于非再入组[12.7（9.3; 18.0）ng / mL，P <0.001]。多元分析表明，血浆DAO水平（HR = 1.102，P <0.05）和肝性脑病（HE）（HR = 5.018，P <0.05）是失代偿性肝硬化6个月再入院的独立因素。预测6时，DAO水平显示出接收器工作特征曲线下的面积大于HE（0.769 vs. 0.598，P <0.05）和Child-Pugh-Turcotte（CPT）得分（0.769 vs. 0.652，P <0.05）月再入院率，最佳临界值为19.7 ng / mL。此外，血浆DAO水平（HR = 1.184，P <0。05）是一个独立因素，在6个月的随访中，复发性HE的发生率AUROC高于CPT评分（0.905 vs. 0.738，P <0.05）。结论血浆DAO水平> 19.7 ng / mL可以预示HBV相关性失代偿性肝硬化患者6个月的再次入院率很高。